Bend Research signs deal with Bristol-Myers Squibb
Will provide formulation development and clinical manufacturing services
Bend Research, a US-based drug formulation development and manufacturing company, has signed a three-year drug discovery and development services agreement with Bristol-Myers Squibb (B-MS).
Under the terms of the agreement, B-MS will use Bend Research's formulation development and manufacturing services for preclinical and clinical development.
Bend Research, based in Oregon, will also manufacture drug product intermediates and drug products at its cGMP facility for B-MS clinical trials.
As part of the agreement, Bend Research is making its proprietary spray-dried dispersion (SDD) technology available to B-MS. The company says its technology has been successfully applied to compounds at various phases of development, from preclinical studies to Phase III clinical trials.